MOLOGEN AG receives approval for clinical study with cell-based gene therapy against renal cancer

The Berlin-based biotechnology company MOLOGEN AG has received approval from the responsible German health authority, the Paul-Ehrlich-Institut, to carry out a phase I/II clinical study with its innovative new MGN1601 cancer medicine. MGN1601 is a cell-based gene therapy for the treatment of advanced renal cancer.

The responsible ethics committee has also agreed to the execution of the study.

It is intended that the study will be carried out at 3 different study centers in Germany and will be led by PD Dr. Steffen Weikert. The participating study centers will be the Charité in Berlin, the University clinic in Bonn and the Hannover Medical School.

According to current plans, the study is likely to start in the fourth quarter of the year, when all preparations have been completed.


MOLOGEN AG, a biopharmaceutical company based in Berlin, specializes in the research and development of innovative medicines based on DNA structures. Activities focus on product developments for the treatment of cancer and vaccines for serious infections.

MOLOGEN was founded in 1998 and is among the few biotechnology companies in the world with well-tolerated, DNA-based cancer treatment in the clinical development stage.

MOLOGEN AG shares are listed in the Prime Standard of Deutsche Börse (ISIN DE 0006637200).

Disclaimer concerning prognoses

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.